Core Viewpoint - The Chinese vaccine industry is facing intense price competition, leading to significant profit declines for many companies. The China Vaccine Industry Association has called for members to resist disorderly low-price competition and adhere to fair pricing practices to stabilize the market and promote innovation [1][2][3]. Group 1: Industry Challenges - The price war in the vaccine industry has intensified, with the price of the bivalent HPV vaccine dropping to as low as 27.5 yuan per dose, and flu vaccines reaching as low as 5.5 yuan per dose [4][6]. - In the first three quarters of this year, 71.43% of A-share vaccine companies reported a decline in net profit, with notable losses from companies like Wantai Biological Pharmacy and BCG Biological [6][7]. Group 2: Association's Initiative - The China Vaccine Industry Association has issued an initiative to promote high-quality development in the vaccine sector by advocating for self-discipline, innovation, and fair competition [2][3]. - The initiative emphasizes compliance with national laws and industry self-regulation, urging members to set prices based on production costs and market demand, while strictly prohibiting bidding below cost [2][3]. Group 3: Long-term Outlook - Experts believe that if the association's initiative is effectively implemented, it could lead to a more orderly competitive landscape, enhancing the industry's sustainability and improving vaccine safety and efficacy [3][7]. - The vaccine industry is seen as a crucial segment of the biopharmaceutical sector, with potential for growth as public health awareness and innovation capabilities improve [7].

Core Viewpoint - The Chinese Vaccine Industry Association has issued an initiative to combat chaotic price competition in the vaccine industry, advocating for self-discipline and innovation to promote high-quality development in the sector [4][5]. Group 1: Industry Challenges - The vaccine industry is experiencing intense price wars, with the price of the bivalent HPV vaccine dropping to as low as 27.5 yuan per dose, and flu vaccines reaching as low as 5.5 yuan per dose [7][9]. - In the first three quarters of this year, 71.43% of A-share vaccine companies reported a decline in net profit, with notable losses from companies like Wantai Biological Pharmacy and BCG Biological [8][9]. Group 2: Association's Initiative - The initiative calls for all members of the association to adhere to the Vaccine Administration Law and the Price Law, ensuring fair and legal pricing based on production costs and market demand [4][5]. - The association emphasizes the need to resist disorderly low-price competition and prohibits bidding below cost, aiming to stabilize market prices and improve product quality [4][6]. Group 3: Long-term Outlook - If effectively implemented, the initiative could lead to a more orderly competitive landscape, enhancing the industry's sustainable development and improving the safety and efficacy of vaccine products [5][6]. - Companies are encouraged to increase R&D investment to develop differentiated products, optimize production processes, and explore international markets to mitigate risks and enhance competitiveness [10].

"透视图"是36氪新推出的轻量化数据图文栏目——以数据透视趋势，以图片呈现要点。 "Talk is Cheap. Show me the data." 作者丨黄绎达 今年公费三价流感疫苗在部分省份中标价低至5.5元/支，刷新历史新低。业内人士指出，这一现象折射出疫苗行业整体进入"降价周期"。 36氪制图 价格下探的背后，一方面是主力接种人群（0—9岁儿童）数量减少，市场需求走弱；另一方面，Me-too类产品扎堆，同质化竞争加剧，九价HPV疫苗便是典 型案例。 40 - 行业均值。 20 - 沃森生物 0 -20 华兰疫苗 -40 - -60 2023 202 2021 2022 毛利率同比下滑 | 万泰生物 | 百克生物 | 华兰生物 | 沃森生物 | 智飞生物 | | --- | --- | --- | --- | --- | | 0 | | | | | | 0 | 0 | -10.9pct | | | | 0 | 0 | -12.9pct | | | | ● | ● | C | 0 | | | 0 | 0 | | | | | -16.9pct ● | 0 | 0 | 0 | | | 0 | | | | | ...

Core Points - Sinovac Biotech Ltd. received a delisting determination letter from Nasdaq due to the failure to submit its 2024 annual report by the extended deadline of November 11, 2025 [1][3] - The company intends to request a hearing to delay the delisting process, which must be submitted by November 19, 2025, to trigger a 15-day suspension of the delisting process [1][3] - The delay in submitting the annual report is attributed to a change in the auditing firm, with the previous firm resigning on April 15, 2025, leading to the appointment of UHY LLP to assist with the audit and report preparation [1][3] Company Background - Sinovac was founded in 2001 and has undergone several changes in its listing status, moving from OTCBB to AMEX and then to Nasdaq [4] - The company has been embroiled in a control dispute since 2016, with significant conflicts between founder Yin Weidong and co-founder Pan Aihua over management and privatization efforts [5][6] Financial Performance - Sinovac's sales peaked at $19.4 billion in 2021 due to the approval of its CoronaVac vaccine, up from $510.6 million in 2020 [7] - However, the company reported a sales decline of 13.6% year-on-year to $121.3 million in the first half of 2024, with a net loss of $68.6 million [7] - The company has a stable core business with several vaccines on the market, but internal control deficiencies remain unresolved [7]

Core Insights - Hualan Vaccine's stock price decreased by 2.02% on November 20, trading at 22.34 CNY per share with a market capitalization of 13.43 billion CNY [1] - The company has seen a year-to-date stock price increase of 33.63%, but a recent decline of 5.62% over the past five trading days [1] Financial Performance - For the period from January to September 2025, Hualan Vaccine reported a revenue of 806 million CNY, a year-on-year decrease of 15.81%, and a net profit attributable to shareholders of 132 million CNY, down 50.51% year-on-year [2] - Cumulative cash dividends since the company's A-share listing amount to 1.037 billion CNY, with 957 million CNY distributed over the past three years [3] Shareholder Structure - As of October 20, 2025, the number of shareholders for Hualan Vaccine stands at 17,000, with an average of 35,332 circulating shares per person [2] - The top ten circulating shareholders include notable entities such as the China Southern Asset Management Co., which has reduced its holdings by 43,990 shares [3]

Core Viewpoint - The investment outlook for the pharmaceutical and bioproducts industry in 2026 indicates a potential recovery in demand and improvement in fundamentals and valuations, particularly in the traditional Chinese medicine sector [1] Group 1: Traditional Chinese Medicine - Short-term pressure from the base is expected to ease, with channel inventory clearing accelerating [1] - There is optimism for demand recovery by the end of the year, along with opportunities for fundamental and valuation improvements [1] - The brand extension space for traditional Chinese medicine consumer companies is broad, supported by innovation [1] Group 2: Blood Products - Attention is drawn to the "14th Five-Year Plan" for plasma station construction and industry consolidation progress [1] - Demand for immunoglobulin and factor products is expected to increase, along with new product development [1] Group 3: Vaccine Industry - Focus on the sales improvement of key products and the progress of innovative pipelines [1] - Policy developments and international expansion of vaccines are anticipated to further drive corporate growth [1] Group 4: Pharmaceutical Retail - The transformation and reform in the pharmaceutical retail sector are progressing steadily [1] - Future catalysts for growth are being monitored [1] Group 5: Pharmaceutical Distribution - The revenue side of the pharmaceutical distribution industry is showing steady improvement [1] - Attention is on payment collection and the "14th Five-Year Plan" [1]

Traditional Chinese Medicine - The short-term pressure on the industry base is expected to gradually ease, with channel adjustments accelerating and a recovery in demand anticipated by year-end, leading to improvements for most companies on a low base [1] - The current valuation of the sector is at a low level, with institutional holdings being low, indicating potential for valuation improvement as the fundamentals of the traditional Chinese medicine industry continue to improve [1] - Long-term transformation is underway, with companies actively transitioning towards biopharmaceuticals and chemical drug innovation to create a second growth curve, and the consumer goods nature of traditional Chinese medicine companies offers significant brand extension opportunities [1] Blood Products - The supply side is expected to see an increase in the number of plasma stations as local "14th Five-Year" plans are implemented, with ongoing industry consolidation and mergers anticipated [2] - On the demand side, while the short-term price of albumin is under pressure, there is significant growth potential for demand in immunoglobulin and factor products, with ongoing research and development of new products [2] - The variety of blood products is expected to increase, which will drive profit margins from plasma extraction [2] Vaccines - The industry is facing ongoing operational pressures, but there is optimism for improved sales and contributions from new products [3] - Recent policies related to commercial insurance, medical prevention integration, and industry mergers provide a solid foundation for future development in the vaccine sector [3] - The expansion of vaccine companies into international markets is accelerating, with expectations for progress in overseas market development [3] Pharmaceutical Retail - The industry is showing clear signs of marginal improvement, with better funding conditions and sustained demand for four categories of drugs, leading to expected same-store sales growth [4] - The sector's valuation is at historical lows, with low institutional holdings, and there is anticipation for demand recovery due to respiratory diseases and increased industry concentration [4] - Long-term transformation is being actively pursued by leading pharmacies, with pilot projects expected to yield incremental contributions and valuation recovery by 2026 [4] Pharmaceutical Distribution - The growth of medical insurance expenditures is stable, providing long-term market momentum [5] - The high entry barriers for new players indicate potential for increased industry concentration [5] - Innovative business models are accelerating growth and contributing additional revenue [5] State-Owned Enterprise Reform - The policy framework for state-owned enterprise reform has matured, with clear reform directions and ongoing implementation of market value management and merger policies [6] - The ongoing "14th Five-Year" plan is expected to improve the operations and valuations of related enterprises [6]

Report Investment Rating - No investment rating information provided in the report Core View - The market expects the stock index to continue its long - term and steady upward trend. The 14th Five - Year Plan focuses on technology, and the technology sector is a long - term direction. The domestic liquidity environment is expected to remain loose, with residents likely to increase their allocation of equity assets, and external funds may flow in as the Fed cuts interest rates and the RMB appreciates. Near the end of the year, funds are relatively cautious, and the market style is more balanced compared to the third quarter [2] Summary by Directory 1. Stock Index Futures Market - **IF Contracts**: The previous day's closing prices of IF contracts (current month, next month, next quarter, and the quarter after next) were 4583.40, 4565.20, 4532.20, and 4489.00 respectively, with increases of 23.40, 22.20, 20.00, and 21.20, and increases of 0.51%, 0.49%, 0.44%, and 0.47% respectively. The trading volumes were 25910.00, 76820.00, 14405.00, and 5478.00, and the open interests were 29702.00, 156324.00, 67558.00, and 18583.00, with changes of - 3947.00, - 2502.00, - 388.00, and 316.00 respectively [1] - **IH Contracts**: The previous day's closing prices of IH contracts were 3018.00, 3011.00, 3006.40, and 2996.20 respectively, with increases of 17.40, 16.60, 15.60, and 13.60, and increases of 0.58%, 0.55%, 0.52%, and 0.46% respectively. The trading volumes were 8705.00, 36365.00, 6657.00, and 1812.00, and the open interests were 9339.00, 61909.00, 18559.00, and 5430.00, with changes of - 1795.00, - 1076.00, 283.00, and 134.00 respectively [1] - **IC Contracts**: The previous day's closing prices of IC contracts were 7116.60, 7054.80, 6875.40, and 6664.00 respectively, with changes of - 15.60, - 1.60, 0.40, and - 9.60, and changes of - 0.22%, - 0.02%, 0.01%, and - 0.14% respectively. The trading volumes were 24997.00, 83682.00, 17690.00, and 6223.00, and the open interests were 21873.00, 141911.00, 61676.00, and 23052.00, with changes of - 9350.00, 2214.00, 1590.00, and 39.00 respectively [1] - **IM Contracts**: The previous day's closing prices of IM contracts were 7390.40, 7298.20, 7068.80, and 6838.60 respectively, with changes of - 38.60, - 31.00, - 26.60, and - 28.20, and changes of - 0.52%, - 0.42%, - 0.37%, and - 0.41% respectively. The trading volumes were 37059.00, 149890.00, 27892.00, and 12626.00, and the open interests were 34672.00, 201080.00, 85839.00, and 42548.00, with changes of - 10135.00, 11495.00, - 716.00, and 1475.00 respectively [1] - **Inter - month Spreads**: The current inter - month spreads of IF, IH, IC, and IM were - 18.20, - 7.00, - 61.80, and - 92.20 respectively, compared to previous values of - 14.60, - 6.00, - 73.00, and - 93.80 [1] 2. Stock Index Spot Market - **Major Indexes**: The previous day's values of the CSI 300, SSE 50, CSI 500, and CSI 1000 indexes were 4588.29, 3020.35, 7122.75, and 7387.21 respectively, with changes of 0.44%, 0.58%, - 0.40%, and - 0.82% respectively. The trading volumes (in billions of shares) were 172.92, 48.20, 162.79, and 238.39, and the total trading amounts (in billions of yuan) were 3852.30, 995.51, 2567.55, and 3671.73 [1] - **CSI 300 Industry Indexes**: The previous day's values of different CSI 300 industry indexes showed various changes. For example, the energy, raw materials, and telecommunications sectors had increases of 2.48%, 2.54%, and 1.08% respectively, while the main consumption, pharmaceutical, and IT sectors had decreases of - 0.33%, - 0.65%, and - 0.60% respectively [1] 3. Futures - Spot Basis - **CSI 300 Basis**: The previous day's basis values of IF contracts (current month, next month, next quarter, and the quarter after next) relative to the CSI 300 were - 4.89, - 23.09, - 56.09, and - 99.29 respectively [1] - **SSE 50 Basis**: The previous day's basis values of IH contracts relative to the SSE 50 were - 2.35, - 9.35, - 13.95, and - 24.15 respectively [1] - **CSI 500 Basis**: The previous day's basis values of IC contracts relative to the CSI 500 were - 6.15, - 67.95, - 247.35, and - 458.75 respectively [1] - **CSI 1000 Basis**: The previous day's basis values of IM contracts relative to the CSI 1000 were 3.19, - 89.01, - 318.41, and - 548.61 respectively [1] 4. Other Domestic and Overseas Indexes - **Domestic Indexes**: The previous day's values of the SSE Composite Index, Shenzhen Component Index, SME Board Index, and ChiNext Index were 3946.74, 13080.09, 7943.55, and 3076.85 respectively, with changes of 0.18%, 0.00%, - 0.18%, and 0.25% respectively [1] - **Overseas Indexes**: The previous day's values of the Hang Seng Index, Nikkei 225, S&P 500, and DAX Index were 25830.65, 48702.98, 6642.16, and 23204.14 respectively, with changes of - 0.38%, - 3.22%, 0.38%, and 0.13% respectively [1] 5. Macroeconomic Information - **China - Japan Relations**: China has notified Japan of the suspension of Japanese aquatic product imports. Japan's wrong remarks on Taiwan have damaged the political foundation of China - Japan relations, and China will take counter - measures if necessary [2] - **Domestic Policies**: Deputy Premier Zhang Guoqing emphasized the digital and intelligent transformation of the manufacturing industry and the innovation and development of state - owned enterprises. The National Immigration Administration has expanded the number of ports issuing one - time Taiwan Resident Permits to 100. Russia will implement a visa - free policy for Chinese citizens soon. The Beijing - Tianjin - Hebei region has signed a cooperation plan for the entire industrial chain of free trade zones [2] 6. Industry Information - **Real Estate**: The cumulative sales volume of second - hand homes in key cities increased slightly in the first 10 months of this year, with market activity declining in October. The sales volume in November is expected to recover month - on - month but face pressure year - on - year, and prices may continue to adjust [2] - **Organic Silicon**: The organic silicon industry is discussing production cuts, which are expected to be implemented gradually in early December [2] - **Vaccine Industry**: The China Vaccine Industry Association has issued an initiative against "involution - style" competition to maintain market price stability [2] - **Photovoltaic and Energy Storage**: The 8th China International Photovoltaic and Energy Storage Industry Conference issued the "Chengdu Declaration" to promote capacity structure optimization and industry self - regulation [2] - **Memory Market**: Due to a shortage of key chips, memory prices are expected to rise by about 50% by the second quarter of 2026, with traditional LPDDR4 at the highest risk of price increases [2] 7. Stock Index Views - **Market Performance**: The three major US indexes rose. The previous trading day saw a divergence in the stock index, with the non - ferrous metals and petrochemical sectors leading the gains and the comprehensive and real estate sectors leading the losses. The market trading volume was 1.74 trillion yuan. On November 18, the margin trading balance increased by 2.581 billion yuan to 2.484901 trillion yuan [2]

Group 1: Market Overview - A-shares indices opened higher with the Shanghai Composite Index up 0.35%, Shenzhen Component Index up 1.03%, and ChiNext Index up 1.79% [1] Group 2: Institutional Insights - Huatai Securities continues to recommend cyclical sectors such as aviation, oil transportation, and road infrastructure, citing improved industrial production and export conditions, as well as a moderate recovery in consumer data [2] - The aviation sector is expected to see continued recovery in revenue levels due to low supply growth, industry self-regulation, and a low base effect [2] - The oil transportation sector is anticipated to maintain high prosperity driven by multiple factors including OPEC+/Americas production increases and low oil prices [2] - The road infrastructure sector is seen as having upward potential due to attractive dividend yields and increased insurance fund allocations [2] Group 3: Industry Focus - CITIC Construction Investment is optimistic about the traditional Chinese medicine industry, expecting demand to recover by year-end and improvements in fundamentals and valuations [3] - The blood products sector is highlighted for its focus on the "14th Five-Year Plan" for plasma station construction and industry consolidation [3] - The vaccine industry is monitored for sales improvements of key products and progress in innovative pipelines, with policies and international expansion expected to drive further development [3] - The pharmaceutical retail sector is undergoing steady transformation, with attention on multi-faceted catalysts for growth [3] - The pharmaceutical distribution sector shows stable revenue growth, with a focus on receivables and the "14th Five-Year Plan" [3]

Market Overview - The market experienced narrow fluctuations yesterday, with both the Shanghai Composite Index and the ChiNext Index closing in the green. The total trading volume in the Shanghai and Shenzhen markets was 1.73 trillion, a decrease of 200.2 billion compared to the previous trading day [1]. Sector Performance - The sectors that saw the highest gains included precious metals, military industry, and aquaculture, while sectors such as Hainan, gas, and film and television box office experienced declines. By the end of the trading day, the Shanghai Composite Index rose by 0.18%, and the ChiNext Index increased by 0.25% [1]. Investment Recommendations Huatai Securities - Huatai Securities continues to recommend cyclical aviation, trading in oil transportation, and allocation in highways. The firm notes that external uncertainties have settled, leading to a recovery in industrial production and export sentiment, along with a mild rebound in consumer data. Specifically, they expect: 1. Aviation: October ticket prices continue to improve, supported by low supply growth and a low base, indicating a sustained recovery in industry profitability. 2. Oil Transportation: Multiple favorable factors, including OPEC+/U.S. production increases and low oil prices, are expected to maintain high activity levels in the oil transportation sector. 3. Highways: With insurance funds beginning year-end allocations, the highway sector is anticipated to have upward potential due to attractive dividend yields [2]. CITIC Securities - CITIC Securities is optimistic about the traditional Chinese medicine industry, anticipating a recovery in demand by year-end and subsequent improvements in fundamentals and valuations. They highlight: - The easing of short-term base pressure and accelerated channel inventory clearance. - The potential for innovative areas to create a second growth curve, with significant brand extension opportunities for Chinese medicine consumer goods. - Attention to the blood products sector regarding the "14th Five-Year Plan" for plasma stations and industry consolidation, as well as the vaccine sector's product sales and innovation pipeline [3]. Tianfeng Securities - Tianfeng Securities suggests focusing on the recovery opportunities in the liquor sector, noting a "volume increase, price drop" trend during the 2025 Double Eleven shopping festival. Key points include: - Traditional e-commerce platforms saw major liquor prices fall below critical levels due to inventory pressures, while emerging channels like instant retail and Douyin experienced growth. - Liquor companies are actively combating counterfeiting and stabilizing prices through authorized and unauthorized listings. - The industry is shifting from price wars to value reconstruction, emphasizing high-quality products and refined channel operations. The current dividend returns from leading liquor companies are attractive, and consumer spending is expected to gradually recover [4].